Summary & Overview
CPT 0488U: Unity Fetal Antigen NIPT for Alloimmunization
CPT code 0488U designates a Proprietary Laboratory Analysis (PLA) for the Unity Fetal Antigen™ NIPT from BillionToOne Laboratory. This cell–free DNA sequencing test detects specific fetal antigens (Rh, C, c, D, E, Duffy (Fya), and Kell (K)) in pregnancies complicated by maternal alloimmunization to identify fetuses at risk for Hemolytic Disease of the Fetus and Newborn (HDFN). As a PLA code tied to a single manufacturer and assay, CPT code 0488U clarifies coding for payers and providers when reporting this proprietary prenatal screening.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication provides a national overview of clinical context, coding considerations, and typical sites of service for this lab-based prenatal screening. Readers will find concise benchmarks and policy context relevant to coverage and billing of proprietary noninvasive prenatal tests, an explanation of the clinical utility in alloimmunized pregnancies, and what payers commonly evaluate when considering coverage for PLA-designated assays. Data not available in the input are identified explicitly where applicable.
Billing Code Overview
CPT code 0488U is a Proprietary Laboratory Analyses (PLA) code that applies exclusively to the Unity Fetal Antigen™ NIPT offered by BillionToOne Laboratory, BillionToOne Inc. The test uses cell–free DNA sequencing from maternal blood to detect the presence or absence of specific fetal antigens — including Rh, C, c, D, E, Duffy (Fya), and Kell (K) — for pregnancies in which the pregnant person has alloimmunization. The result helps identify pregnancies at increased risk for Hemolytic Disease of the Fetus and Newborn (HDFN) and guides which pregnancies will most benefit from additional fetal monitoring.
Service type: Proprietary noninvasive prenatal screening using cell–free DNA sequencing
Typical site of service: Clinical laboratory processing with blood draw performed in outpatient phlebotomy settings, obstetrics clinics, or hospital outpatient departments
Clinical & Coding Specifications
Clinical Context
A pregnant patient with a history of red blood cell alloimmunization presents for risk stratification of Hemolytic Disease of the Fetus and Newborn (HDFN). The ordering clinician—typically a maternal-fetal medicine specialist, obstetrician, or an obstetric nurse practitioner—documents maternal antibody specificity (for example, anti-D, anti-Kell, anti-c) and gestational age. A maternal blood sample is collected and sent to BillionToOne Laboratory for the proprietary Unity Fetal Antigen™ NIPT reported under 0488U. The laboratory performs cell-free DNA sequencing to determine presence or absence of fetal antigens (Rh, C, c, D, E, Duffy (Fya), Kell (K)). Results are returned to the ordering clinician who uses the information to decide need and timing for targeted fetal monitoring (ultrasound Doppler surveillance for middle cerebral artery peak systolic velocity), intrauterine intervention, or postpartum neonatal planning. Typical sites of service include outpatient obstetrics clinics, maternal-fetal medicine clinics, and hospital outpatient laboratories. The service type is laboratory genetic testing/Proprietary Laboratory Analysis (PLA) for prenatal alloimmunization assessment.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use when billing only the professional interpretation component if the lab separates professional and technical components and the provider is billing for interpretation. |